Cargando…

X-linked inhibitor of apoptosis protein (XIAP) predicts disease-free survival in BRAFV600E mutant papillary thyroid carcinoma in middle eastern patients

BACKGROUND: X-linked inhibitor of apoptosis (XIAP) is the most potent caspase inhibitory IAP family member and its over-expression is implicated in aggressive behavior of various solid tumors, including papillary thyroid carcinoma (PTC). BRAFV600E mutation is the most common oncogenic event in PTC a...

Descripción completa

Detalles Bibliográficos
Autores principales: Parvathareddy, Sandeep Kumar, Siraj, Abdul K., Bu, Rong, Iqbal, Kaleem, Al-Rasheed, Maha, Al-Haqawi, Wael, Annaiyappanaidu, Padmanaban, Siraj, Nabil, Ahmed, Saeeda O., Al-Sobhi, Saif S., Al-Dayel, Fouad, Al-Kuraya, Khawla S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9790986/
https://www.ncbi.nlm.nih.gov/pubmed/36578953
http://dx.doi.org/10.3389/fendo.2022.1054882
_version_ 1784859298754461696
author Parvathareddy, Sandeep Kumar
Siraj, Abdul K.
Bu, Rong
Iqbal, Kaleem
Al-Rasheed, Maha
Al-Haqawi, Wael
Annaiyappanaidu, Padmanaban
Siraj, Nabil
Ahmed, Saeeda O.
Al-Sobhi, Saif S.
Al-Dayel, Fouad
Al-Kuraya, Khawla S.
author_facet Parvathareddy, Sandeep Kumar
Siraj, Abdul K.
Bu, Rong
Iqbal, Kaleem
Al-Rasheed, Maha
Al-Haqawi, Wael
Annaiyappanaidu, Padmanaban
Siraj, Nabil
Ahmed, Saeeda O.
Al-Sobhi, Saif S.
Al-Dayel, Fouad
Al-Kuraya, Khawla S.
author_sort Parvathareddy, Sandeep Kumar
collection PubMed
description BACKGROUND: X-linked inhibitor of apoptosis (XIAP) is the most potent caspase inhibitory IAP family member and its over-expression is implicated in aggressive behavior of various solid tumors, including papillary thyroid carcinoma (PTC). BRAFV600E mutation is the most common oncogenic event in PTC and is also known to be associated with aggressive clinico-pathological characteristics. In this study, we investigated the prevalence of XIAP expression in more than 1600 PTCs from Middle Eastern ethnicity and its prognostic value to predict disease-free survival (DFS), in combination with the BRAFV600E mutation. METHODS: Clinical data, XIAP expression by immunohistochemistry and BRAF mutation status were analyzed in 1640 Saudi PTC patients seen at our institute between 1988 - 2020. RESULTS: BRAFV600E mutation was found in 910 of 1640 patients (55.5%) and was significantly correlated with older age, extrathyroidal extension, bilaterality, multifocality and lymph node metastasis, but was not an independent predictor of DFS. XIAP was over-expressed in 758 of 1640 (46.2%) and was associated with aggressive clinico-pathological features. It was also found to be an independent prognostic marker for DFS (HR = 1.28, 95% CI = 1.02 – 1.60, P = 0.0342). XIAP overexpression was correlated with presence of BRAFV600E mutation in PTC patients. Interestingly, we found the ability to predict shorter DFS was 2.7-fold higher in PTCs with over-expression of XIAP and BRAFV600E mutation compared to patients with high XIAP and wild-type BRAFV600E status (HR = 2.74, 95% CI = 2.19 – 3.44, p < 0.0001). CONCLUSION: XIAP expression is an independent predictor of prognosis in Middle Eastern PTC patients. Combination of XIAP expression and BRAFV600E mutation can synergistically improve the DFS prediction in PTC patients, which may help clinicians to establish the most appropriate initial care and long-term surveillance strategies.
format Online
Article
Text
id pubmed-9790986
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-97909862022-12-27 X-linked inhibitor of apoptosis protein (XIAP) predicts disease-free survival in BRAFV600E mutant papillary thyroid carcinoma in middle eastern patients Parvathareddy, Sandeep Kumar Siraj, Abdul K. Bu, Rong Iqbal, Kaleem Al-Rasheed, Maha Al-Haqawi, Wael Annaiyappanaidu, Padmanaban Siraj, Nabil Ahmed, Saeeda O. Al-Sobhi, Saif S. Al-Dayel, Fouad Al-Kuraya, Khawla S. Front Endocrinol (Lausanne) Endocrinology BACKGROUND: X-linked inhibitor of apoptosis (XIAP) is the most potent caspase inhibitory IAP family member and its over-expression is implicated in aggressive behavior of various solid tumors, including papillary thyroid carcinoma (PTC). BRAFV600E mutation is the most common oncogenic event in PTC and is also known to be associated with aggressive clinico-pathological characteristics. In this study, we investigated the prevalence of XIAP expression in more than 1600 PTCs from Middle Eastern ethnicity and its prognostic value to predict disease-free survival (DFS), in combination with the BRAFV600E mutation. METHODS: Clinical data, XIAP expression by immunohistochemistry and BRAF mutation status were analyzed in 1640 Saudi PTC patients seen at our institute between 1988 - 2020. RESULTS: BRAFV600E mutation was found in 910 of 1640 patients (55.5%) and was significantly correlated with older age, extrathyroidal extension, bilaterality, multifocality and lymph node metastasis, but was not an independent predictor of DFS. XIAP was over-expressed in 758 of 1640 (46.2%) and was associated with aggressive clinico-pathological features. It was also found to be an independent prognostic marker for DFS (HR = 1.28, 95% CI = 1.02 – 1.60, P = 0.0342). XIAP overexpression was correlated with presence of BRAFV600E mutation in PTC patients. Interestingly, we found the ability to predict shorter DFS was 2.7-fold higher in PTCs with over-expression of XIAP and BRAFV600E mutation compared to patients with high XIAP and wild-type BRAFV600E status (HR = 2.74, 95% CI = 2.19 – 3.44, p < 0.0001). CONCLUSION: XIAP expression is an independent predictor of prognosis in Middle Eastern PTC patients. Combination of XIAP expression and BRAFV600E mutation can synergistically improve the DFS prediction in PTC patients, which may help clinicians to establish the most appropriate initial care and long-term surveillance strategies. Frontiers Media S.A. 2022-12-12 /pmc/articles/PMC9790986/ /pubmed/36578953 http://dx.doi.org/10.3389/fendo.2022.1054882 Text en Copyright © 2022 Parvathareddy, Siraj, Bu, Iqbal, Al-Rasheed, Al-Haqawi, Annaiyappanaidu, Siraj, Ahmed, Al-Sobhi, Al-Dayel and Al-Kuraya https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Endocrinology
Parvathareddy, Sandeep Kumar
Siraj, Abdul K.
Bu, Rong
Iqbal, Kaleem
Al-Rasheed, Maha
Al-Haqawi, Wael
Annaiyappanaidu, Padmanaban
Siraj, Nabil
Ahmed, Saeeda O.
Al-Sobhi, Saif S.
Al-Dayel, Fouad
Al-Kuraya, Khawla S.
X-linked inhibitor of apoptosis protein (XIAP) predicts disease-free survival in BRAFV600E mutant papillary thyroid carcinoma in middle eastern patients
title X-linked inhibitor of apoptosis protein (XIAP) predicts disease-free survival in BRAFV600E mutant papillary thyroid carcinoma in middle eastern patients
title_full X-linked inhibitor of apoptosis protein (XIAP) predicts disease-free survival in BRAFV600E mutant papillary thyroid carcinoma in middle eastern patients
title_fullStr X-linked inhibitor of apoptosis protein (XIAP) predicts disease-free survival in BRAFV600E mutant papillary thyroid carcinoma in middle eastern patients
title_full_unstemmed X-linked inhibitor of apoptosis protein (XIAP) predicts disease-free survival in BRAFV600E mutant papillary thyroid carcinoma in middle eastern patients
title_short X-linked inhibitor of apoptosis protein (XIAP) predicts disease-free survival in BRAFV600E mutant papillary thyroid carcinoma in middle eastern patients
title_sort x-linked inhibitor of apoptosis protein (xiap) predicts disease-free survival in brafv600e mutant papillary thyroid carcinoma in middle eastern patients
topic Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9790986/
https://www.ncbi.nlm.nih.gov/pubmed/36578953
http://dx.doi.org/10.3389/fendo.2022.1054882
work_keys_str_mv AT parvathareddysandeepkumar xlinkedinhibitorofapoptosisproteinxiappredictsdiseasefreesurvivalinbrafv600emutantpapillarythyroidcarcinomainmiddleeasternpatients
AT sirajabdulk xlinkedinhibitorofapoptosisproteinxiappredictsdiseasefreesurvivalinbrafv600emutantpapillarythyroidcarcinomainmiddleeasternpatients
AT burong xlinkedinhibitorofapoptosisproteinxiappredictsdiseasefreesurvivalinbrafv600emutantpapillarythyroidcarcinomainmiddleeasternpatients
AT iqbalkaleem xlinkedinhibitorofapoptosisproteinxiappredictsdiseasefreesurvivalinbrafv600emutantpapillarythyroidcarcinomainmiddleeasternpatients
AT alrasheedmaha xlinkedinhibitorofapoptosisproteinxiappredictsdiseasefreesurvivalinbrafv600emutantpapillarythyroidcarcinomainmiddleeasternpatients
AT alhaqawiwael xlinkedinhibitorofapoptosisproteinxiappredictsdiseasefreesurvivalinbrafv600emutantpapillarythyroidcarcinomainmiddleeasternpatients
AT annaiyappanaidupadmanaban xlinkedinhibitorofapoptosisproteinxiappredictsdiseasefreesurvivalinbrafv600emutantpapillarythyroidcarcinomainmiddleeasternpatients
AT sirajnabil xlinkedinhibitorofapoptosisproteinxiappredictsdiseasefreesurvivalinbrafv600emutantpapillarythyroidcarcinomainmiddleeasternpatients
AT ahmedsaeedao xlinkedinhibitorofapoptosisproteinxiappredictsdiseasefreesurvivalinbrafv600emutantpapillarythyroidcarcinomainmiddleeasternpatients
AT alsobhisaifs xlinkedinhibitorofapoptosisproteinxiappredictsdiseasefreesurvivalinbrafv600emutantpapillarythyroidcarcinomainmiddleeasternpatients
AT aldayelfouad xlinkedinhibitorofapoptosisproteinxiappredictsdiseasefreesurvivalinbrafv600emutantpapillarythyroidcarcinomainmiddleeasternpatients
AT alkurayakhawlas xlinkedinhibitorofapoptosisproteinxiappredictsdiseasefreesurvivalinbrafv600emutantpapillarythyroidcarcinomainmiddleeasternpatients